“Deucravacitinib in Moderate to Severe Plaque Psoriasis: 5-Year, Long-Term Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials”. SKIN The Journal of Cutaneous Medicine 9, no. 2 (March 17, 2025): s532. Accessed May 9, 2026. https://skin.dermsquared.com/skin/article/view/3309.